• 1
    Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective of two decades of clinical research. Semin Oncol 1988; 15: 27899.
  • 2
    Blackstein M, Eisenhauer EA, Wierzbicki R, Yoshida S. Epirubicin in extensive small-cell lung cancer: a Phase II study in previously untreated patients. A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1990; 8: 3859.
  • 3
    Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity and adverse effects of an Adriamycin analogue. J Clin Oncol 1986; 4: 42539.
  • 4
    Daniel CP, Dexter TM. The role of growth factors in haemopoietic development: clinical and biological implications. Cancer Metastasis Rev 1989; 8: 25362.
  • 5
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 20714.
  • 6
    Hryniuk W. The importance of dose intensity in the outcome of chemotherapy. In: DeVitaVTJr, HellmanS, RosembergSA, editors. Important advances in oncology 1988. Philadelphia: JB Lippincott, 1988: 12141.
  • 7
    Riccardi A, Danova M, Wilson G, Ucci G, Dormer P, Mazzini G, et al. Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res 1988; 48: 623845.
  • 8
    Aglietta M, Piacibello W, Sanavio F, Stacchini A, Aprà F, Schena M, et al. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony stimulating factor. J Clin Invest 1989; 83: 5517.
  • 9
    Baldwin GC, Gasson JC, Kaufman SE, Quan SG, Williams RE, Avalos R, et al. Non hematopoietic tumor cells express functional GM-CSF receptors. Blood 1989; 73: 10337.
  • 10
    Lieschke GJ, Cebon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony stimulating factor. Blood 1989; 74: 263443.
  • 11
    DeVries EGE, Biesma B, Willemse PHB, Mulder NH, Stern AC, Aalders JG, et al. A double-blind placebo-controlled study with granulocyte-macrophage colony stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991; 51: 11622.
  • 12
    Dodwell DJ, Gurney H, Thatcher N. Dose intensity in cancer chemotherapy. Br J Cancer 1990; 61: 78994.
  • 13
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SH, Edison M, Phelps R, et al. Randomized trial of high vs standard dose etoposide and cisplatin in extensive stage small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1991; 10: 819.
  • 14
    Steward WP, Scarffe JH, Austin R, Bonnem E, Thatcher N, Morgenstern, et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions: a Phase I dose-toxicity study. Br J Cancer 1989; 59: 1425.
  • 15
    Gianni AM, Bregni M, Siena S, Orazi A, Stern AC, Gandola L, et al. Recombinant human granulocyte-macrophage colony stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 76878.
  • 16
    Bruno E, Miller ME, Hoffman R. Interacting cytokines regulate in vitro human megakaryocytopoiesis. Blood 1989; 73: 6717.
  • 17
    Furman WL, Fairclough DL, Huhn RD, Charles BP, Norbert S, William PP, et al. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 1991; 9: 10228.
  • 18
    Antman KS, Griffin JD, Elias A, Socinsky MA, Ryan L, Cannistra SA, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319: 5938.
  • 19
    Herrman F, Schulz G, Lindemann A, Meyennburg W, Osten W, Krumwier D, et al. Hematopoietic response in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989; 7: 15967.
  • 20
    Riccardi A, Danova M, Paccagnella A, Giordano M, Favaretto A, Panozzo M, et al. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony stimulating factor. Ann Hematol 1993; 66: 18593.